MedPage Today

EGFR Testing in Advanced NSCLC: Real-World Data Show Major Gaps

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
ascopubs.org

EGFR mutation testing trends for patients with metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) in Queensland, Australia from 2014-2021.

Association between patient tumour characteristics and five-year survival in Nigerian patients with breast cancer.
Seeking Alpha

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
The Financial

Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment

The FINANCIAL — Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of ...
ascopubs.org

EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing

Trends in Lung Cancer Incidence and Mortality (1990-2019) in the United States: A Comprehensive Analysis of Gender and State-Level Disparities A total of 7,413 tumor specimens were tested. The ...
Nasdaq

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the ...

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...
Medscape

FDA OKs First Liquid Biopsy for Lung Cancer Mutation

The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...